Keller Lab | MDC Berlin

Our utmost goal is to identify and target crucial cancer cell vulnerabilities while sparing normal tissue. From discovery approaches to validation and preclinical testing. Aiming for clinical application.

Cancer originates from normal cells through genetic and epigenetic alterations. By employing forward genomic screening we start from a known gene mutation or cancer-associated condition and investigate the path that results in a manifest malignancy. Major further focus areas of the lab include: oncoprotein-induced disturbance of post-translational protein modifications, in particular SUMOylation, and sensing of DNA damage; constitutively activated B-cell receptor and chemokine receptor signaling; and molecular cancer imaging and theranostics.

Group Leader

Prof. Dr. med. Ulrich Keller

Team

Markus Schick, M.Sc., Postdoc

Matthias Wirth, PD Dr. rer. nat., Scientist

Stefan Habringer, Dr. med. Dr. univ., Clinician scientist

Jolanta Slawska, M.Sc., Technical assistant (affiliation: TUM)

Konstandina Isaakidis, B.Sc., Technical assistant

Veronika Schulze, M.Sc., Technical assistant

Stefanos Alexandros Bamopoulos, Clinician scientist

Nikita Nikita, PhD student

Le Zhang, MD student

Minh Ho, B.Sc., Technical assistant

Yingfen Hong, MD student (TUM)

Josefina Doffo, M.Sc., PhD student (affiliation: TUM)

Elena Rohleder, Dr. med., Clinician scientist

Sven Liebig, Clinician scientist

Francis Baumgartner, Dr. med., Clinician scientist

Uta Demel, Dr. med., Clinician scientist

Richard Lewis, MD student (affiliation: TUM/Charité)

Stavroula Litsiou, Pharmacist, PhD student

Laura Schmalbrock, Dr. med., Clinician scientist

Enio Gjerga, M.sc., Bioinformatician, Postdoc

Currently, the Keller Group focuses on the following research projects:

Myc-associated cancer biology

Functional genomic screening

Aberrant Ub/SUMO activity in cancer

Chemokine receptor signaling

Functional imaging and theranostics

February 10, 2021 in Mol Cell

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma

M. Heider
R. Eichner
J. Stroh
V. Morath
A. Kuisl
J. Zecha
J. Lawatscheck
K. Baek
A.K. Garz
M. Rudelius
F.C. Deuschle
U. Keller
S. Lemeer
M. Verbeek
K.S. Götze
A. Skerra
W.A. Weber
J. Buchner
B.A. Schulman
B. Kuster
V. Fernández-Sáiz
F. Bassermann

February 02, 2021 in Br J Cancer

The SUMO pathway in pancreatic cancer: insights and inhibition

C. Schneeweis
Z. Hassan
M. Schick
U. Keller
G. Schneider

February 01, 2021 in Clin Res Cardiol

Assessment of coronary artery disease during hospitalization for cancer treatment

S.M. Mrotzek
A. Lena
S. Hadzibegovic
R. Ludwig
F. Al-Rashid
A.A. Mahabadi
R.I. Mincu
L. Michel
L. Johannsen
L. Hinrichs
M. Schuler
U. Keller
S.D. Anker
U. Landmesser
T. Rassaf
M.S. Anker
M. Totzeck

February 01, 2021 in Lancet Oncol

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

January 01, 2021 in Clin Cancer Res

Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial

C.A. Voltin
J. Mettler
L. van Heek
H. Goergen
H. Müller
C. Baues
U. Keller
J. Meissner
K. Trautmann-Grill
A. Kerkhoff
M. Fuchs
S. Sasse
B. von Tresckow
M. Dietlein
P. Borchmann
A. Engert
C. Kobe
P.J. Bröckelmann

December 17, 2020 in Blood

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

S. Reinke
P.J. Bröckelmann
I. Iaccarino
M. Garcia-Marquez
S. Borchmann
F. Jochims
M. Kotrova
K. Pal
M. Brüggemann
E. Hartmann
S. Sasse
C. Kobe
S. Mathas
M. Soekler
U. Keller
M. Bormann
A. Zimmermann
J. Richter
M. Fuchs
B. von Tresckow
P. Borchmann
H. Schlößer
M. von Bergwelt-Baildon
A. Rosenwald
A. Engert
W. Klapper

December 17, 2020 in Blood

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

December 14, 2020 in Cancers

Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy

M. Wirth
M. Schick
U. Keller
J. Krönke

December 09, 2020 in Biomedicines

Authentication of primary murine cell lines by a microfluidics-based lab-on-chip system

Y. Hong
N. Singh
S. Bamopoulos
E. Gjerga
L.K. Schmalbrock
K. Balabanian
M. Schick
U. Keller
M. Wirth

December 01, 2020 in Ann Hematol

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A - results of a retrospective analysis

M. Pouyiourou
A. Meyer
A. Stroux
A. Viardot
P. La Rosée
G. Maschmeyer
D. Kämpfe
C. Kahl
V. Vucinic
A. Monecke
C. Hirt
T. Weber
J. Meissner
M. Witzens-Harig
S. Böttcher
H. Schmalenberg
R. Marks
G. Prange-Krex
F. Kroschinsky
E. Hauf
U. Keller
K. Koch
W. Klapper
M. Herold
C.W. Scholz

Deutsche Forschungsgemeinschaft (SFB 824, SFB 1335)
Deutsche Krebshilfe
Sander Stiftung
EU/BMBF Horizon 2020
German Cancer Consortium (DKTK)
Stiftung Charité
Berlin Institute of Health (BIH)
Berliner Krebsgesellschaft